<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Altimmune Inc — News on 6ix</title>
<link>https://6ix.com/company/altimmune-inc</link>
<description>Latest news and press releases for Altimmune Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 20:19:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/altimmune-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835457478dffbe2df0e28f9.webp</url>
<title>Altimmune Inc</title>
<link>https://6ix.com/company/altimmune-inc</link>
</image>
<item>
<title>Altimmune Announces Proposed Underwritten Public Offering of Securities</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-announces-proposed-underwritten-public-offering-of-securities</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-announces-proposed-underwritten-public-offering-of-securities</guid>
<pubDate>Wed, 22 Apr 2026 20:19:00 GMT</pubDate>
<description>GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced it has commenced an underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase an equivalent number of shares of its common stock (or pre-funded warrants in lieu thereof), and, in lieu of common stock to certain investors, pre-funded warrants</description>
</item>
<item>
<title>Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-announces-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-7</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-announces-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-7</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of</description>
</item>
<item>
<title>Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-march-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-march-5-2026</guid>
<pubDate>Thu, 26 Feb 2026 12:30:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor</description>
</item>
<item>
<title>Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-announces-closing-75-million-225400098</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-announces-closing-75-million-225400098</guid>
<pubDate>Thu, 29 Jan 2026 22:54:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct off</description>
</item>
<item>
<title>Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-announces-pricing-75-million-022500804</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-announces-pricing-75-million-022500804</guid>
<pubDate>Wed, 28 Jan 2026 02:25:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has entered into a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. The offering is expected to result in gro</description>
</item>
<item>
<title>Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-receives-fda-breakthrough-therapy-123000425</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-receives-fda-breakthrough-therapy-123000425</guid>
<pubDate>Mon, 05 Jan 2026 12:30:00 GMT</pubDate>
<description>Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDAGAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agoni</description>
</item>
<item>
<title>Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-announces-pemvidutide-achieved-key-113000502</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-announces-pemvidutide-achieved-key-113000502</guid>
<pubDate>Fri, 19 Dec 2025 11:30:00 GMT</pubDate>
<description>Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without plateauing Favorable tolerability profile of pemvidutide preserved at 48 weeks, reinforced by low treatment-related discontinuation rate End-of-Phase 2 meeting with FDA supports advancing to registrational Phase 3 trial in MASH patients with moderate to advanced liver fibrosis Conf</description>
</item>
<item>
<title>Altimmune Announces CEO Transition and Succession Plan</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-announces-ceo-transition-succession-123000524</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-announces-ceo-transition-succession-123000524</guid>
<pubDate>Mon, 01 Dec 2025 12:30:00 GMT</pubDate>
<description>Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and metabolic diseases, today announced a CEO succession plan under which Vipin Garg, Ph.D. will step down as the Company’s President and Chief Executi</description>
</item>
<item>
<title>Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-participate-piper-sandler-37th-123000716</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-participate-piper-sandler-37th-123000716</guid>
<pubDate>Wed, 26 Nov 2025 12:30:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. Details are as follows: Conference: Piper Sandler 37th Annual Healthcare ConferenceDate/Time: Wednesday, December 3, 2025 at 2:30</description>
</item>
<item>
<title>Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-announces-publication-impact-phase-135100531</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-announces-publication-impact-phase-135100531</guid>
<pubDate>Tue, 11 Nov 2025 13:51:00 GMT</pubDate>
<description>24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondary endpoints, including reductions in liver fat, inflammation and biomarkers of fibrosis GAITHERSBURG, Md., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseas</description>
</item>
<item>
<title>Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-presents-ai-based-analysis-130500422</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-presents-ai-based-analysis-130500422</guid>
<pubDate>Fri, 07 Nov 2025 13:05:00 GMT</pubDate>
<description>AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement Pemvidutide demonstrated significant reductions in liver fibrosis and improvements in non-invasive tests vs. placebo at 24 weeks GAITHERSBURG, Md., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today ann</description>
</item>
<item>
<title>Altimmune Announces Third Quarter 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-announces-third-quarter-2025-120000351</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-announces-third-quarter-2025-120000351</guid>
<pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
<description>48-week Data from Phase 2b IMPACT Trial of Pemvidutide in MASH Expected Before Year End End-of-Phase 2 Meeting with FDA for MASH Program Scheduled in Fourth Quarter Executive Leadership Strengthened with Appointments of Chief Medical Officer, Chief Commercial Officer, and Chief Legal Officer Cash, cash equivalents and short-term investments of $211 million as of September 30, 2025 Webcast to be held today, November 6, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alt</description>
</item>
<item>
<title>Altimmune to Participate in Two Upcoming Investor Conferences</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-participate-two-upcoming-investor-123000389</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-participate-two-upcoming-investor-123000389</guid>
<pubDate>Wed, 05 Nov 2025 12:30:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for one-on-one meetings at the following investor conferences: Stifel 2025 Healthcare ConferenceWednesday, November 12, 2025Fireside Chat at 10:00 a.m. ET Jefferies Global Healthcare Confe</description>
</item>
<item>
<title>Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-announces-early-completion-enrollment-123000924</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-announces-early-completion-enrollment-123000924</guid>
<pubDate>Mon, 03 Nov 2025 12:30:00 GMT</pubDate>
<description>Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option On track to complete the 24-week treatment period and announce topline results in 2026 GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the completion of patient enrollment in RECLAIM, a</description>
</item>
<item>
<title>Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-report-third-quarter-2025-113000815</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-report-third-quarter-2025-113000815</guid>
<pubDate>Thu, 30 Oct 2025 11:30:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it will report its third quarter 2025 financial results on Thursday, November 6, 2025. Altimmune management will host a conference call at 8:30 a.m. ET on November 6 to discuss financial results and provide a business update. The conference call will be webcast l</description>
</item>
<item>
<title>Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-to-present-phase-2b-impact-data-on-pemvidutide-in-mash-in-late-breaking-oral-podium-presentation-and-late-breaking-poster-at-aasld-the-liver-meetingr-2025</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-to-present-phase-2b-impact-data-on-pemvidutide-in-mash-in-late-breaking-oral-podium-presentation-and-late-breaking-poster-at-aasld-the-liver-meetingr-2025</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>Oral presentation to highlight 24-week efficacy and safety data Poster to feature results of AI-based analyses of liver fibrosis reduction GAITHERSBURG, Md.,</description>
</item>
<item>
<title>Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-appoints-industry-veteran-christophe-113000302</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-appoints-industry-veteran-christophe-113000302</guid>
<pubDate>Mon, 29 Sep 2025 11:30:00 GMT</pubDate>
<description>Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chie</description>
</item>
<item>
<title>Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide </title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-appoints-industry-veteran-christophe-arbet-engels-md-phd-as-chief-medical-officer-to-drive-next-phase-of-clinical-development-of-pemvidutide</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-appoints-industry-veteran-christophe-arbet-engels-md-phd-as-chief-medical-officer-to-drive-next-phase-of-clinical-development-of-pemvidutide</guid>
<pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
<description>Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and</description>
</item>
<item>
<title>Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-appoints-accomplished-commercial-executive-113000948</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-appoints-accomplished-commercial-executive-113000948</guid>
<pubDate>Mon, 15 Sep 2025 11:30:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. Richardson joins the Company with more than 30 years of experience in sales and marketing, commercial, corporate and business development across a range</description>
</item>
<item>
<title>Altimmune to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/altimmune-inc/news/altimmune-participate-upcoming-investor-conferences-113000509</link>
<guid isPermaLink="true">https://6ix.com/company/altimmune-inc/news/altimmune-participate-upcoming-investor-conferences-113000509</guid>
<pubDate>Tue, 26 Aug 2025 11:30:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences: Wells Fargo Healthcare Conference in Boston, MA Friday, September 5, 2025 One-on-one meetings only H.C. Wainwright Global Investment Conference in New York, NY T</description>
</item>
</channel>
</rss>